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Abstract
Background: Executive functions (EF) in Alzheimer’s disease (AD), classically related to the prefrontal cortex, have been
forgotten in mild stages, given more importance to temporal lobe associated disorders, such as memory. The study of
disexecutive syndrome (DS) has been relegated to advanced stages of the disease. Our goal is to demonstrate that EF
are already present in amnesic mild cognitive impairment (aMCI). Furthermore, we are interested in knowing whether
poor scores in EF tests are related to the progression to AD or another kind of dementia.
Methods: We studied patients with aMCI (n = 81) and healthy controls (n = 142) from neurological departments of
several centers of Basque Country with a cross-sectional design. Patients underwent a complete neuropsychological
evaluation, neuroimaging testing APOE genotype and 3 year of prospective follow-up.
Results: In the first visit, patients with aMCI showed more alterations in tests that evaluate EF such as Stroop, trail-making
and categorical verbal fluency. More alterations were also found in NPI scale (P <0.05). Stroop and Trail-Making test were
not associated with the future development of AD, but fluency (p = 0.01) and apathy (p = 0.031) did. No patient
developed a different kind of dementia different from AD.
Conclusions: DS is a broad concept not confined to frontal lobes, and can be found in early stages of aMCI. DS impacts
negatively on patient autonomy and may have prognostic value.
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Background
Executive functions (EF), a term coined by Lezak [1] fol-
lowing the footsteps of Luria, are those mental capacities
necessary for formulating goals, planning how to achieve
them, and carrying out the plans effectively, encompassing
tasks such as inhibition, interference control, working
memory and cognitive flexibility. EF allow us to work with
ideas, take time to think before acting, adapt to new and
unexpected situations, avoid temptations and stay focused
on something.
About the limits of EF located in prefrontal cortex, there
is a certain lack of consensus and today its spectrum in-
clude not only cognitive aspects but also behavioral
aspects. Impairment or loss of these functions compromises
a person’s capacity to maintain an independent, construct-
ively self-serving, and socially productive life [1, 2]. This is
the case of Alzheimer disease (AD) [3]
Neurodegeneration in AD typically begins in the medial
temporal lobe [4] leading to episodic memory deficits and
to an inability to learn new information. As long as the dis-
ease progresses other brain areas will be impaired, produ-
cing language disorders, apraxia, visuospatial and executive
disorders, and social and emotional dysfunctions. There are
atypical forms of AD such as frontal variant, with a severe
and disproportionate early alteration in the frontal func-
tions and greater prominence of neurofibrillary tangles in
the frontal cortex than in patients with classical Alzheimer’s
disease [5].
However, in general terms we can face the model of the
prototypical AD to frontotemporal dementia (FTD), in
which degeneration begins in frontal and temporal lobes
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and the initial symptoms include deficits in executive func-
tions and language, often with episodic memory relatively
intact.
Many authors [6] believe that executive functions are
relatively preserved in early stages of AD, being impaired
later in the course of the disease, reflecting a moderate to
severe cognitive impairment, related to the severity and
duration of AD [7]. However, this is a controversial matter,
and during the past 20 years, the literature has evolved
and reported that AD patients were early impaired on
executive functions [3, 8] especially those called “cold“ ex-
ecutive functions, because the corresponding cognitive
processes tend not to have an emotional involvement and
are relatively mechanical or logic. Unlike ”hot” executive
functions in which emotions are more relevant, such as
the experience of reward-punishment, the social behavior
of each individual or the capacity of making decisions
based on social and emotional aspects [9, 10].
Mild cognitive impairment (MCI), is a condition in which
there are cognitive deficits involving specific domains in the
absence of significant functional impact [11]. Current clas-
sifications recognize subtypes, depending on the presence
or absence of impairment in episodic memory, denominat-
ing them amnestic mild cognitive impairment (aMCI) or
non amnestic mild cognitive impairment. We can also sub-
classificate patients based on whether cognitive dysfunc-
tions are single or multiple (single-domain, multi-domain)
[12]. These classifications and sub-classifications may repre-
sent the prodromal situation of different types of dementia.
According to this classification aMCI is often a previous
stage of AD, and in one year 12 % of mild amnestic cogni-
tive impairments will progress to AD [11].
Our study aims is to demonstrate that DS in AD is
present in previous stages, such as aMCI. We also are
interested in knowing whether the association of mem-
ory problems and executive impairment in aMCI leads
to a different type of dementia such as FTD and to study
the relationship between the scores of the EF and the
progression from aMCI to AD.
Methods
Subjects
From a sample of 296 subjects recruited consecutively
from the neurological departments of several centers of
the Basque Country during one year period, we selected
for this study only patients with aMCI (n = 81) and healthy
controls (n = 142), the remaining 73 corresponded to
patients with EA on the first visit.
And we followed up them yearly during a period of three
years, using an extensive battery of tests and neuropsycho-
logical scales.
Neurologists with experience in cognitive impairment
and neuropsychologists, who have previously worked to-
gether in other projects, evaluated all the patients and they
used validated scales in Spanish in order to get inter-rater
reliability:
– Mini-Mental State Examination (MMSE) [13, 14].
– Seven-minute neurocognitive screening battery [15,
16] including: a) Benton Orientation Test (temporal
orientation), b) The Clock Test (visuospatial and
visual-constructional capacity), c) Facilitating free
recall (modification from the paradigm proposed by
Buschke et. al. to evaluate episodic memory) and d)
categorical verbal fluency (semantic memory and
word retrieval strategy).
– Clinical Dementia Rating (CDR) for global
assesment [17].
– Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) [18] we assessed the list of words
(memory), Trail-Making test parts A and B (attention
and executive functions) and Boston test (language,
nomination of images).
– Behavioral disturbances in patients were evaluated
using the Neuropsychiatric Inventory (NPI) [19,
20] and disability by the Interview for
Deterioration in Daily Living Activities in
Dementia (IDDD) [21].
– Stroop A, B,C [22] (attention and executive
functions)
– Ideomotor praxis were also systematically evaluated
using Barcelona test [23].
EF were assessed by using Trail-making, Stroop and
categorical verbal fluency test.
The results of these evaluations allow us to classify pa-
tients in different diagnostic groups.
The diagnosis of patients with aMCI was based on
Petersen’s [24] and Winblad [25] criteria. Patients had
memory complaints corroborated by an informant, repre-
senting a decline from a previous level of functioning
given their age and educational level. The score in the
CDR scale was required to be 0.5, and performance in
relation to other cognitive functions and daily living activ-
ities was required to be normal.
Healthy control subjects were scored within the nor-
mal ranges for age and educational level in psychometric
testing, with a CDR score of 0.
AD diagnosis was based on the DSM IV and NINCDS-
ADRDA criteria for probable and possible AD
For patients with aMCI, evaluation also included routine
blood tests: hematology, biochemistry, thyroid stimulating
hormone, vitamin B12 levels, syphilis serology and neuro-
imaging test: CT scan or MRI. APOE genotyping was per-
formed in all patients.
The exclusion criteria included: severe comorbidities
making adequate follow-up unlikely, acute psychiatric dis-
eases, previous cerebrovascular diseases (transient ischemic
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attacks, stroke or intracranial hemorrhage), other neurode-
generative diseases and the absence of a reliable informant.
Records and informed consent
A specific database (Microsoft Access 2013) was designed
and declared to the Spanish Data Protection Agency. The
study was approved by the Ethics Committee of Cruces
Hospital (Barakaldo, Spain). All patients signed informed
consent to undergo the examination. The study was con-
ducted in accordance with the Declaration of Helsinki
concerning medical research in human subjects.
Design of the study
In this cross-sectional study, we analyzed in the first visit
the scores from each group of patients: Control and
aMCI group (diagnostic category) and progression and
stable group (progression category, defined by the future
clinic progression or not of controls to aMCI and of
aMCI to AD during the follow up period).
Statistical analysis
Data were analyzed using SPSS 22v. for Windows.
In the first visit demographic variables between groups
(aMCI and controls) and the test scores were studied, in
order to determine if there were early differences. The
independent variable was the diagnostic category (aMCI
and controls) and the dependent variable the scores of
the test. As the data were not normally distributed, to
establish the differences, we used non-parametric test: U
of Mann–Whitney and W of Wilcolson.
Then, we focused in the first visit of aMCI patients and
we studied if EF, besides other factors (sex, age at first visit,
years of schooling, APOE genotype and scores of other test
than those evaluating EF) could be related to the progres-
sion of the disease. Now the independent variable was the
presence or absence of clinical progression. Quantitative
dependent variables (Test scores, age at first visit and years
of schooling) were analyzed using U of Mann–Whitney
and W of Wilcolson and qualitative variables (sex and pres-
ence or absence of APOE ε4 genotype) using chi-square.
For those significant or close to the signification values we
applied a model of binary logistic regression to perform a
multivariate analysis.
A correlation analysis was also done (Pearson Correlation
Coefficient) between scores that measure EF and IDDD, as
well as between EF and apathy and memory in MCI.
Results
There were no differences in age and sex between patients
with cognitive impairment and controls. There were differ-
ences in years of schooling: higher values were found in
controls than in aMCI (Table 1). Controls and aMCI also
differ in MMSE scores, clock test, IDDD and NPI
scale (p <0.01 in agitation, depression, anxiety, apathy,
irritability and in changes in appetite). There was no
difference in unilateral and bilateral praxis.
Regarding the scores for the EF test between controls
and aMCI (Table 2), there were statistically significant dif-
ferences in Stroop A, Stroop B, Stroop C, Trail-Making A
time, in addition to all Trail-Making B items.
During the three year period of follow up, completed
by 57 % of controls and 63 % of aMCI, 6 patients (4 %)
progressed from control to aMCI and 21 patients (26 %)
progressed to AD, nobody progressed to dementia from
control group.
We also analyzed if there were differences in the EF test
scores between those patients with aMCI who experience
clinical progression to dementia compared to those who
remained stable (Table 3). There were no statistically
significant differences in Trail-Making and STROOP test
(although STROOP C p = 0.082) but we found differences
in verbal fluency (p <0.01).
On the other hand, we assessed if there were other condi-
tions that may influence the clinical progression, such as
sex, age at first visit, years of schooling, apoE4 genotype or
scores on memory tests, clock test or NPI scale (Table 4).
Focusing on these factors that may influence the progres-
sion we found significant differences in APOE 4 genotype
(p = 0.02), so those with at least one AP0E4 positive allele
have a higher risk of progressing to dementia, OR of 3,294
(95 % CI 1,174- 9,243). No differences were found in gen-
der. There were also significant differences in Facilitating
free recall, list 2 and 3 and delayed recall of the list 1 of
CERAD. Regarding the NPI Scale the total sum of all
items has offered no meaningful information, but the ana-
lysis item by item did, and apathy reached a significance
level of 0.031.
Table 1 Summary of baseline characteristics of study participants
Controls (n = 142) aMCI (n = 81) P value
Women 80 (56.3 %) 42 (51.9 %) 0.58
Men 62 (43.7 %) 39 (48.1 %)
schooling 9.48 (4.87) 8.20 (4.16) 0.02
Age First visit 70.97 (8.43) 71.51 (7.14) 0.69
3 years progression 6 (4.2 %) a 21 (25.9 %)b <0.01
APO ε4 alele 34 (23.9 %) 29 (35.8 %) 0.09
MMSE 28.1 (1.82) 26.51 (2.51) <0.01
Denomination 13.41 (1.97) 12.21 (2.36) <0.01
Clock test 6.28 (1.34) 5.65 (1.59) <0.01
Unilateral Praxis 15.60 (0.89) 15.45 (1.19) 0.65
Bilateal praxis 7.05 (1.35) 6.80 (1.50) 0.123
IDDD 33 (0.25) 37.30 (4.67) <0.01
NPI total 0.4 (1.04) 5.53 (7.12) <0.01
aProgression to aMCI, bProgression to EA. Mean (standar deviation)
Note: Values that are statistically significant are indicated in bold
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Multivariate analysis of significative variables with binary
logistic regression determine that only recall of the list 1 of
CERAD remains significative (p = 0.01).
There was a discrete correlation (p = 0.01, r = 0.31) be-
tween the time spent in the performance of Trail Making
B and IDDD scale. Correlations between memory tests,
apathy and EF test in MCI showed also significant but
subtle associations (Table 5).
During the follow-up none of the 27 people (controls or
aMCI) who progressed showed symptoms suggestive of
other types of dementia different from Alzheimer’s disease.
Discussion
The results of our study, in agreement with previous ones,
[26–31] show that executive changes, measured in our
case by Stroop test, trail-Making (Part B more relevant
than A), are a very early finding in the course of the dis-
ease; This changes are present in aMCI.
Some authors [27, 28, 32, 33] point out the beginning of
the executive impairment in mild stages of AD, specifically
after the failures in episodic memory and before changes
in language and cognition. Considering them the second
most common neuropsychological impairment in mild
AD followed by memory failures [3].
It should be mentioned to illustrate this precocity of ap-
pearance, one study [34] in which patients with subjective
memory complaints (without mild cognitive impairment,
dementia or other neurological or psychiatric disease)
with confirmation of preclinical AD through the analisis
of CSF, after two years of follow up began to show a de-
cline in memory and executive functions.
Some of the most widely used tests of executive abilities,
are the Wisconsin Card Sorting Task (WCST), the Stroop
Test, and the Trail Making Test [28, 35]. But in order to
increase the sensitivity to detect a dysexecutive syndrome
and bring the assessment to the conditions of real life, it
was developed the Behavioral Assessment of Dysexecutive
Syndrome (BADS) [36], tool used to confirm the occur-
rence of disturbances in executive functions in aMCI and
early AD, asserting that in most of the patients were al-
tered other aspects besides memory. However sometimes
deficits no related to memory are difficult to detect in a
brief cognitive assessment.
Another recently developed tool for the assessment of
cognitive and behavioral executive functions is the GRE-
FEX battery. Used in one study whose authors said that
up to 80 % of mild to moderate AD patients have alter-
ations in EF. This battery includes verbal fluency which
can be measure EF, but there is a lack of consensus on
whether it should be considered within this group or
Table 2 In aMCI. Comparison between EF test scores
Test Control aMCI P value
Stroop A 86.89 (18.53) 75.46 (18.61) <0.01
Stroop B 57.12 (12.42) 48.99 (14.48) <0.01
Stroop C 28.91(9.75) 21.89 (11.15) <0.01
Trail Making A Items - 24.85 (1.31) 0.19
Trail Making A time 62.74 (32.45) 83.93 (34.59) <0.01
Trail Making A mistakes 0.17 (0.86) 0.23 (0.61) 0.13
Trail Making B items 23.11 (4.57) 19.45 (7.32) <0.01
Trail Making B time 128.05 (48.10) 166.49 (43.75) <0.01
Trail Making B mistakes 0.75 (1.24) 1.69 (1.94) <0.01
Verbal fluency 18.71(5.98) 14.68 (5.13) <0.01
Mean (standard deviation)
Note: Values that are statistically significant are indicated in bold
Table 3 Progression vs stable, differences between EF test scores
Progression Stable P value
Stroop A 70.72 (18,03) 77.08 (18.70) 0.22
Stroop B 48.11 (16.51) 49.28 (13.89) 0.84
Stroop C 19.17 (12.73) 22.81 (10.53) 0.08
Trail Making A Items -(−) 24.79(1.51) 0.55
Trail Making A time 82.17 (32.90) 84.53 (35.44) 0.81
Trail Making A mistakes 0.17 (0.71) 0.25 (0.59) 0.67
Trail Making B items 21.78 (5.77) 18.66 (7.67) 0.10
Trail Making B time 169.39 (29.27) 165.51(47.88) 0.74
Trail Making B mistakes 1.56 (1.10) 1.74 (2.16) 0.60
Verbal fluency 12.28 (4.66) 15.49 (5.06) 0.01
Note: Values that are statistically significant are indicated in bold
Table 4 Other factors that may influence the progression
Progression Stable P value
Schooling 10.83 (5.28) 7.77 (3.50) 0.26
First visit age 72.17 (5,37) 70.87 (7,79) 0.66
Women 21.43 % 78.57 % 0.338
Men 30.77 % 69.23 %
APOE 4 (+) 41.38 % 58.62 % 0.02
APOE4 (−) 17.65 % 82.35 %
MMSE 26.39 (1.82) 26.77 (2,63) 0.11
NPI total 6.64 (7.46) 5.14 (7.02) 0.24
Apathy (NPI) 2.58 (2.87) 1.21 (2.37) 0.031
Denomination 11.57 (3.06) 12.44 (2.04) 0.376
Clock test 5.42 (1.80) 5.70 (1.50) 0.32
Facilitating-free recall 11.81 (3.37) 1379 (2.91) 0.01
CERAD list 1 2.29 (1.06) 2.98 (1.42) 0.05
CERAD list 2 4.00 (1.30) 4.66 (1.46) 0.04
CERAD list 3 4.48 (1.33) 5.76 (1.56) <0.01
Recall list 1 CERAD 2.10 (1.76) 3.16 (1.99) 0.04
Recognition CERAD 16.05 (2.89) 16.69 (2.75) 0.39
Mean (estándar deviation)
Note: Values that are statistically significant are indicated in bold
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Table 5 Correlations between memory test, EF test and apathy
Fluency Stroop A Stroop B Stroop C TM A items TM A time TM A mistakes TM B items TM B time TM B mistakes Apathy








NS NS NS NS
Immediate recall r = 0.33
p < 0.01




NS NS r = 0.23
p = 0,05
NS r = −0.42
p < 0.01
NS
free recall r = 0.43
p < 0.01




NS r = −0.43
p < 0.01
NS r = 0.41
p < 0.01
NS r = −0.33
p = 0.01
NS
Facilitating recall NS NS NS r = 0.23
p = 0.46
NS NS NS NS NS NS NS




NS r = 0.47
p < 0,01
NS r = −0.34
p < O.01
NS r = 0.33
p < 0.01
NS r = −0.26
p = 0.03
NS
CERAD List of word List 1 r = 0.23
p = 0.04
NS NS NS NS r = −0.40
p < 0.01
NS NS r = − 0.26
p = 0.03
NS NS

























NS r = −0.45
p < 0.01














NS r = −0.52
p < 0.01


































not, in fact it is difficult to frame this dysfunction as a
linguistic, semantic memory, dysexecutive alteration, or
a deficit in processing speed [8, 37].
Apathy is included as a hallmark of the dysexecutive
behavior, around which have emerged previous works
relating it to the progression from MCI to AD and a
thinning of the temporal cortex in aMCI [38–40].
Our study has highlighted the importance of measuring
verbal fluency, through categorical evocation of animals.
Not only because it is early altered in aMCI, but also
because unlike the Trail Making or Stroop, it has been
observed that there is an association between the scores of
fluency and the progression to dementia. Indeed, previous
studies showed a high sensitivity of verbal fluency test for
detecting dementia. Recent prospective neuropsychological
studies indicate that cognitive assessment can be an excel-
lent indicator of future progression of MCI to AD particu-
larly when episodic memory is combined with alterations
in executive control and language tasks [41, 42].
With regard to disease progression, the available litera-
ture suggests that early onset of executive alterations favors
the progression from MCI to AD [10, 32, 41–44]. In our
study we have not been able to prove this assumption
through the scores of Stroop and Trail-Making, This lack
of significance may be explained because only 21 aMCI
progressed to dementia during the three years follow-up at
and it could be difficult to reach an statistical significance.
In our study, no distinction has been made between
single-domain aMCI or multi-domain, but other authors
[32] classified MCI patients into four subgroups (amnestic
versus non amnestic, and single-domain versus multiple-
domain. Planning/problem-solving and working memory,
but not judgment, were impaired in the four subtypes, even
among those with a pure amnestic MCI. Multiple-domain
MCI patients had more severe impairments in planning/
problem-solving and working memory than single-domain
patients, leading to the supposition that they are at highest
risk of imminent dementia comparing with not pure
amnestic MCIs.
Regarding the impact of EF alterations in patient auton-
omy, several publications have highlighted their importance
in real life situations such as handling money or taking
regular medication, with a normal shallow cognitive
assessment [2, 28]. Our data provides a significant cor-
relation between IDDD scale and the time of the Trail-
making type B.
Another discussed aspect is the anatomical basis of
executive functions. Frontal lobe and EF have been trad-
itionally considered as synonymous. In fact neuroimaging
studies have demonstrated the involvement of the frontal
lobe in “cold” executive tasks, with a homogeneous involve-
ment of the prefrontal cortex [45]. However, recent data
have suggested that “cold” executive functions are distrib-
uted over a wide cerebral network which includes posterior
associative cortices [46], subcortical structures and thalamic
ways. Some authors [47] have even linked cerebellar lobes
with executive functions including working memory, multi-
tasking and inhibition.
Currently, a great deal of attention is being paid to
the study of EF and their relationship with the white
matter, and the cortico-cortical brain networks, altered
during the neurodegenerative process of Alzheimer’s
disease [48]. Using advanced imaging techniques such
as diffusion tensor, it has been confirmed the involve-
ment of frontal and posterior brain areas (parietal
lobes) in patients with MCI and impaired EF [49]. In
addition to cingular alterations [50].
Another object of analysis in this study is whether there
is an association between episodic memory and EF. In our
study Buschke modified test or the CERAD’s list of words
are good predictors of progression of the disease.
In AD executive deficits could be explained for the
memory impairment. Some authors [6] suggest that
failure in executive function reflects a selective vulner-
ability within limbic–cortical networks secondary to a
temporal lobe dysfunction. Other authors [8] also de-
tected significant correlations in mild AD and not in
very mild cases between EF and memory. An associ-
ation between verbal fluency with long term memory,
but not with short term memory has also found. In
addition, many of the proposed neuropsychological
tests to evaluate executive functions also evaluate atten-
tion [51]. Attention is a complex higher brain function
indispensable to memorize, and this fact may be pos-
sible explanation for these correlations.
The strengths of our study are its multicenter nature,
the correct inclusion of patients into diagnostic categor-
ies, the representativeness of the sample and the broad
battery of neuropsychological tests performed.
Our study design allow us an adequate characterization
of patients and the prospective follow-up provides more
information about the factors associated with the progres-
sion of cognitive impairment.
Aspects that can have a direct application in routine
clinical practice, optimizing resources and to providing
data to support prognostic informations.
This study represents a comprehensive approach to the
dysexecutive syndrom in aMCI with the last informations
published the last years.
Some limitations in our study must be addressed. Our
population comes from a hospital setting. A community-
based study could provide more information. Besides,
the small number of patients who progress from MCI to
AD (consistent with previous papers) makes difficult to
draw conclusions. We have also used the most common
tests for EF, however currently there are extensive bat-
teries that includes not only cognitive but also behav-
ioral aspects.
Blanco Martín et al. BMC Neurology  (2016) 16:88 Page 6 of 8
Conclusions
Dysexecutive syndrome is a part of a set of alterations that
can accompany episodic memory disorder in aMCI, its
relevance lies in the negative impact on patient autonomy
and its role as a predictor of the future development of
dementia.
In our study we have only been able to prove this premise
for the loss of categorical verbal fluency and apathy. We
consider efficient to include systematically an assessment of
both in the routine evaluation of a patient with aMCI.
Regarding the relationship between episodic memory
and EF our data point out to a relationship between them,
but further studies would be required to confirm this
statement.
Abbreviations
AD, Alzheimer’s disease; aMCI, Amnesic mild cognitive impairment; DS,
Disexecutive síndrome; EF, Executive functions; FTD, Frontotemporal dementia.
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